Andere Sprachen Allogene Therapeutics, Inc.

Aktien

A2N6WN

US0197701065

ALLO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
2.89 ^USD	+1.23%		-15.00%	-9.97%

26.04.	Allogene Therapeutics erhält 15 Millionen Dollar Zuschuss vom California Institute for Regenerative Medicine für die Entwicklung von Krebsmedikamenten	MT
15.03.	Allogene Therapeutics reicht $500 Millionen Mixed Shelf ein	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	26.04.
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	26.04.
Allogene Therapeutics Announces Q2 Investor Conference Participation	09.04.
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index	18.03.
Allogene Therapeutics Files $500 Million Mixed Shelf	15.03.
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops	14.03.
Allogene Therapeutics: Q4 Earnings Snapshot	14.03.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	14.03.
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	14.03.
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease	12.03.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update	05.03.
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	28.02.
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	28.02.
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	19.02.
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments	16.02.
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	16.02.
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023	16.02.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	16.01.
North American Morning Briefing : Boeing Drags -2-	08.01.
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic	05.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Allogene Therapeutics, Inc.

Aktien

A2N6WN

US0197701065

ALLO

Andere Sprachen

Filter